12:00 AM
 | 
Feb 22, 2010
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Cyclacel preclinical data

In vitro, seliciclib killed Femara-resistant breast cancer cells by targeting the low molecular weight form of cyclin E, whose overexpression is a...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >